Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aromatase inhibitors: basic and clinical studies.

A M Brodie1, R C Coombes, M Dowsett

  • 1Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland, Baltimore.

Journal of Steroid Biochemistry
|January 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A new way of grading severity of ACL rupture on acute MRI to consider potential for non-surgical healing with the Cross Bracing Protocol: ACL Acute Rupture Characteristics for Healing (ACL-ARCH) MRI criteria.

Journal of science and medicine in sport·2025
Same author

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.

Breast cancer research and treatment·2017
Same author

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study.

British journal of cancer·2015
Same author

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

The AURORA initiative for metastatic breast cancer.

British journal of cancer·2014
Same journal

Preferential nuclear binding of estrogen in the formalin-fixed rat uterus.

Journal of steroid biochemistry·1990
Same journal

Properties of estrogen and hydroxysteroid sulphotransferases in human mammary cancer.

Journal of steroid biochemistry·1990
Same journal

Alterations in the binding characteristics of glucocorticoid receptors from obese Zucker rats.

Journal of steroid biochemistry·1990
Same journal

In vitro inhibition by ketoconazole of human testicular steroid oxidoreductases.

Journal of steroid biochemistry·1990
Same journal

Testing for fluoxymesterone (Halotestin) administration to man: identification of urinary metabolites by gas chromatography-mass spectrometry.

Journal of steroid biochemistry·1990
Same journal

The state transitions of normal and mutant androgen-receptor complexes in human genital skin fibroblasts.

Journal of steroid biochemistry·1990
See all related articles

Aromatase inhibitors like 4-hydroxyandrostenedione (4-OHA) effectively reduce estrogen levels. This shows promise for treating estrogen-dependent conditions, including advanced breast cancer in postmenopausal women.

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Estrogen plays a key role in various conditions, including breast cancer.
  • Aromatase inhibitors offer a potential therapeutic strategy by blocking estrogen production.

Purpose of the Study:

  • To evaluate the efficacy of 4-hydroxyandrostenedione (4-OHA) as an aromatase inhibitor.
  • To assess the impact of 4-OHA on estrogen levels and tumor regression in preclinical models and human patients.

Main Methods:

  • In vitro studies demonstrated 4-OHA's potent aromatase inhibition.
  • Preclinical studies in rats showed reduced ovarian estrogen production and mammary tumor regression.
  • Clinical trials involved administering 4-OHA intramuscularly or orally to postmenopausal breast cancer patients.

Related Experiment Videos

Main Results:

  • 4-OHA significantly reduced serum estradiol levels in all treated patients.
  • Objective responses (partial or complete) were observed in 27% of patients receiving intramuscular 4-OHA.
  • Disease stabilization occurred in 10% of patients, with similar outcomes in the oral 4-OHA group.

Conclusions:

  • 4-hydroxyandrostenedione (4-OHA) is an effective aromatase inhibitor.
  • 4-OHA demonstrates significant efficacy in reducing estrogen levels and achieving clinical responses in advanced breast cancer.
  • Aromatase inhibitors like 4-OHA represent a valuable addition to breast cancer treatment options.